Physician profile
Jean Schwartz
NPI 1619337854
$9,215.55
in general payments reported to CMS, 2019-2025
16 companies · $5,858 in 2025
The $5,858 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,033 · 2022: $1,383 · 2023: $66.82 · 2024: $875 · 2025: $5,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,880 · Travel and Lodging: $589 · Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,880.00 |
| Travel and Lodging | $589.21 |
| Food and Beverage | $330.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $6,697.59 | 2024-2025 | Zilbrysq |
| Biohaven Pharmaceutical Holding Company Ltd. | $685.15 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $541.36 | 2021 | |
| Celgene Corporation | $482.84 | 2022-2024 | Zeposia |
| Sk Life Science, INC. | $173.18 | 2021 | |
| Abbvie INC. | $153.04 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $113.11 | 2022 | |
| Biogen, INC. | $102.85 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $93.69 | 2021 | |
| Ge Healthcare | $37.59 | 2021 | |
| Genentech USA, INC. | $27.39 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $26.89 | 2021 | |
| Emd Serono, INC. | $25.43 | 2021 | |
| Amgen INC. | $24.05 | 2021 | |
| Allergan, INC. | $18.98 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.